Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Calithera Biosci Com (CALA)

Calithera Biosci Com (CALA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Calithera Biosci Com 343 OYSTER POINT BLVD SUITE 200 SOUTH SAN FRANCISCO CA 94080 USA

www.calithera.com P: 650-870-1000

Description:

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 37
Enterprise Value, $K -3,073
Shares Outstanding, K 4,872
Annual Sales, $ 9,750 K
Annual Net Income, $ -39,650 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -6,940 K
EBIT, $ -42,090 K
EBITDA, $ -41,830 K
60-Month Beta -1.09
% of Insider Shareholders 6.60%
% of Institutional Shareholders 0.00%
Float, K 4,551
% Float 93.40%
Short Volume Ratio 0.05

Growth:

1-Year Return -74.67%
3-Year Return -99.96%
5-Year Return -99.99%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 01/01/24
Earnings Per Share ttm -7.20
EPS Growth vs. Prev Year 36.17%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 06/15/22

CALA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 4.19
Interest Coverage -1.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar